348 related articles for article (PubMed ID: 7838159)
1. Spectrum of transcriptional, dimerization, and dominant negative properties of twenty different mutant thyroid hormone beta-receptors in thyroid hormone resistance syndrome.
Collingwood TN; Adams M; Tone Y; Chatterjee VK
Mol Endocrinol; 1994 Sep; 8(9):1262-77. PubMed ID: 7838159
[TBL] [Abstract][Full Text] [Related]
2. Amino acid substitutions of thyroid hormone receptor-beta at codon 435 with resistance to thyroid hormone selectively alter homodimer formation.
Nomura Y; Nagaya T; Tsukaguchi H; Takamatsu J; Seo H
Endocrinology; 1996 Oct; 137(10):4082-6. PubMed ID: 8828460
[TBL] [Abstract][Full Text] [Related]
3. Divergent dimerization properties of mutant beta 1 thyroid hormone receptors are associated with different dominant negative activities.
Hao E; Menke JB; Smith AM; Jones C; Geffner ME; Hershman JM; Wuerth JP; Samuels HH; Ways DK; Usala SJ
Mol Endocrinol; 1994 Jul; 8(7):841-51. PubMed ID: 7984146
[TBL] [Abstract][Full Text] [Related]
4. Thyroid hormone receptor-beta mutants associated with generalized resistance to thyroid hormone show defects in their ligand-sensitive repression function.
Piedrafita FJ; Ortiz MA; Pfahl M
Mol Endocrinol; 1995 Nov; 9(11):1533-48. PubMed ID: 8584031
[TBL] [Abstract][Full Text] [Related]
5. Dominant negative and DNA-binding properties of mutant thyroid hormone receptors that are defective in homodimerization but not heterodimerization.
Kitajima K; Nagaya T; Jameson JL
Thyroid; 1995 Oct; 5(5):343-53. PubMed ID: 8563470
[TBL] [Abstract][Full Text] [Related]
6. Isoform variable action among thyroid hormone receptor mutants provides insight into pituitary resistance to thyroid hormone.
Safer JD; Langlois MF; Cohen R; Monden T; John-Hope D; Madura J; Hollenberg AN; Wondisford FE
Mol Endocrinol; 1997 Jan; 11(1):16-26. PubMed ID: 8994184
[TBL] [Abstract][Full Text] [Related]
7. Understanding the molecular mechanism of dominant negative action of mutant thyroid hormone beta 1-receptors: the important role of the wild-type/mutant receptor heterodimer.
Zhu XG; Yu CL; McPhie P; Wong R; Cheng SY
Endocrinology; 1996 Feb; 137(2):712-21. PubMed ID: 8593822
[TBL] [Abstract][Full Text] [Related]
8. Interaction of human beta 1 thyroid hormone receptor and its mutants with DNA and retinoid X receptor beta. T3 response element-dependent dominant negative potency.
Meier CA; Parkison C; Chen A; Ashizawa K; Meier-Heusler SC; Muchmore P; Cheng SY; Weintraub BD
J Clin Invest; 1993 Oct; 92(4):1986-93. PubMed ID: 8408652
[TBL] [Abstract][Full Text] [Related]
9. N-terminal variants of thyroid hormone receptor beta: differential function and potential contribution to syndrome of resistance to thyroid hormone.
Ng L; Forrest D; Haugen BR; Wood WM; Curran T
Mol Endocrinol; 1995 Sep; 9(9):1202-13. PubMed ID: 7491112
[TBL] [Abstract][Full Text] [Related]
10. Cell type-dependent modulation of the dominant negative action of human mutant thyroid hormone beta 1 receptors.
Wong R; Zhu XG; Pineda MA; Cheng SY; Weintraub BD
Mol Med; 1995 Mar; 1(3):306-19. PubMed ID: 8529109
[TBL] [Abstract][Full Text] [Related]
11. Analysis of the functional role of steroid receptor coactivator-1 in ligand-induced transactivation by thyroid hormone receptor.
Jeyakumar M; Tanen MR; Bagchi MK
Mol Endocrinol; 1997 Jun; 11(6):755-67. PubMed ID: 9171239
[TBL] [Abstract][Full Text] [Related]
12. Functional properties of a mutant T3 receptor beta (R338W) identified in a subject with pituitary resistance to thyroid hormone.
Sasaki S; Nakamura H; Tagami T; Miyoshi Y; Nakao K
Mol Cell Endocrinol; 1995 Aug; 113(1):109-17. PubMed ID: 8674808
[TBL] [Abstract][Full Text] [Related]
13. The function of retinoid X receptors on negative thyroid hormone response elements.
Takeda T; Nagasawa T; Miyamoto T; Hashizume K; DeGroot LJ
Mol Cell Endocrinol; 1997 Apr; 128(1-2):85-96. PubMed ID: 9140079
[TBL] [Abstract][Full Text] [Related]
14. Difference in dominant negative activities between mutant thyroid hormone receptors alpha1 and beta1 with an identical truncation in the extreme carboxyl-terminal tau4 domain.
Nishiyama K; Andoh S; Kitahara A; Natsume H; Mikami T; Genma R; Nakamura H
Mol Cell Endocrinol; 1998 Mar; 138(1-2):95-104. PubMed ID: 9685218
[TBL] [Abstract][Full Text] [Related]
15. A novel TR beta mutation (R383H) in resistance to thyroid hormone syndrome predominantly impairs corepressor release and negative transcriptional regulation.
Clifton-Bligh RJ; de Zegher F; Wagner RL; Collingwood TN; Francois I; Van Helvoirt M; Fletterick RJ; Chatterjee VK
Mol Endocrinol; 1998 May; 12(5):609-21. PubMed ID: 9605924
[TBL] [Abstract][Full Text] [Related]
16. A role for helix 3 of the TRbeta ligand-binding domain in coactivator recruitment identified by characterization of a third cluster of mutations in resistance to thyroid hormone.
Collingwood TN; Wagner R; Matthews CH; Clifton-Bligh RJ; Gurnell M; Rajanayagam O; Agostini M; Fletterick RJ; Beck-Peccoz P; Reinhardt W; Binder G; Ranke MB; Hermus A; Hesch RD; Lazarus J; Newrick P; Parfitt V; Raggatt P; de Zegher F; Chatterjee VK
EMBO J; 1998 Aug; 17(16):4760-70. PubMed ID: 9707435
[TBL] [Abstract][Full Text] [Related]
17. Nuclear corepressors enhance the dominant negative activity of mutant receptors that cause resistance to thyroid hormone.
Tagami T; Jameson JL
Endocrinology; 1998 Feb; 139(2):640-50. PubMed ID: 9449636
[TBL] [Abstract][Full Text] [Related]
18. Very strong correlation between dominant negative activities of mutant thyroid hormone receptors and their binding avidity for corepressor SMRT.
Matsushita A; Misawa H; Andoh S; Natsume H; Nishiyama K; Sasaki S; Nakamura H
J Endocrinol; 2000 Dec; 167(3):493-503. PubMed ID: 11115777
[TBL] [Abstract][Full Text] [Related]
19. An artificial thyroid hormone receptor mutant without DNA binding can have dominant negative effect.
Liu RT; Suzuki S; Takeda T; DeGroot LJ
Mol Cell Endocrinol; 1996 Jun; 120(1):85-93. PubMed ID: 8809742
[TBL] [Abstract][Full Text] [Related]
20. The human thyrotropin-releasing hormone gene is regulated by thyroid hormone through two distinct classes of negative thyroid hormone response elements.
Hollenberg AN; Monden T; Flynn TR; Boers ME; Cohen O; Wondisford FE
Mol Endocrinol; 1995 May; 9(5):540-50. PubMed ID: 7565802
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
